Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis

Our aim was to assess the relationship between serum adalimumab levels, anti-drug antibodies (ADA) and disease activity in patients with axial spondylarthritis (SpA). We have carried out a single-centre cross-sectional study. adalimumab and ADA levels were analysed with ELISA and correlated with SpA...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology international 2019-05, Vol.39 (5), p.841-849
Main Authors: Senabre Gallego, José Miguel, Rosas, Jose, Marco-Mingot, Mariana, García-Gómez, José Alberto, Santos-Soler, Gregorio, Salas-Heredia, Esteban, Pons-Bas, Ana, Barber-Vallés, Xavier, Bernal-Vidal, José Antonio, Cano-Pérez, Catalina, García-Carrasco, Mario, Flores-Pardo, Emilio
Format: Article
Language:English
Subjects:
Adalimumab - blood
Adalimumab - immunology
Adalimumab - therapeutic use
Adolescent
Adult
Aged
Antibodies - immunology
Clinical medicine
Cross-Sectional Studies
Disease
Drug dosages
Female
Hospitals
Humans
Immunoglobulins
Immunotherapy
Laboratories
Male
Medical research
Medicine
Medicine & Public Health
Middle Aged
Monoclonal antibodies
Observational Research
Rheumatoid arthritis
Rheumatology
Severity of Illness Index
Spondylarthropathies - drug therapy
Studies
TNF inhibitors
Treatment Outcome
Tumor Necrosis Factor Inhibitors - blood
Tumor Necrosis Factor Inhibitors - immunology
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor necrosis factor-TNF
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our aim was to assess the relationship between serum adalimumab levels, anti-drug antibodies (ADA) and disease activity in patients with axial spondylarthritis (SpA). We have carried out a single-centre cross-sectional study. adalimumab and ADA levels were analysed with ELISA and correlated with SpA activity using BASDAI and ASDAS scores. Adalimumab cut-off value was calculated to discriminate inactive disease/low disease activity (BASDAI 
ISSN:0172-8172
1437-160X
DOI:10.1007/s00296-019-04288-7